Show simple item record

FieldValueLanguage
dc.contributor.authorXu, Jesse
dc.date.accessioned2022-02-04T03:53:44Z
dc.date.available2022-02-04T03:53:44Z
dc.date.issued2021en_AU
dc.identifier.urihttps://hdl.handle.net/2123/27402
dc.description.abstractAirway stents are the most widely used means of palliative treatment for patients suffering from central airway obstruction (CAO). CAO may occur directly from airway stenosis, respiratory cancers, or tracheobronchomalacia, a symptom of weakening airway cartilage. Current airway stents are constructed using medical-grade silicone or nickel-titanium (nitinol) alloy, that have fixed geometry and are inserted via bronchoscopic surgery. These stents have many shortcomings due to their standardised size and dimensions that are not compatible with the patient’s lung anatomy, causing stent migration, granulation tissue growth, and airway secretions. These incidences will lead to airway restenosis and will require further surgical intervention. In malignant central airway obstructions, patients encounter further morbidity with concomitant intravenous delivery of chemotherapeutics which result in significant systemic side-effect profile. The thesis addresses current shortcomings of improper stent fitting, prevention of granulation tissue formation and local therapy of respiratory cancer relapse, with the development of a controlled drug-eluting stent containing an anti-proliferative drug, paclitaxel. The thesis first evaluates the current state-of-the-art technologies used in the development of respiratory stents to identify knowledge gap withing the field (chapter 1). Subsequently, it evaluates the feasibility of incorporating paclitaxel drug particles into a silicone elastomer that will be used for airway stents and the corresponding drug release profiles from silicone elastomer (chapter 2). Then, alterations on various physicochemical properties of the drug particles and silicone formulations were made to modulate the release kinetics of paclitaxel from the silicone (chapter 3). The efficacy of released paclitaxel was investigated in its ability to control lung cancer (chapter 2) and granulation tissue growth (chapter 5). Finally, the thesis discusses two methods used to develop a more fitting airway stent: 1) using a novel 3D-printing platform in the creation of a surgical guide (chapter 4) and 2) development of a silicone casting platform that is personalisable to individual patient airway geometry (chapter 5).en_AU
dc.language.isoenen_AU
dc.subject3D-Printingen_AU
dc.subjectAirway Stenten_AU
dc.subjectLung Canceren_AU
dc.subjectTracheobronchomalaciaen_AU
dc.subjectPaclitaxelen_AU
dc.subjectCentral Airway Obstructionen_AU
dc.titleDevelopment of 3D-Printed, Drug-Eluting Airway Stents for the Personalised and Local Treatment of Central Airway Pathologiesen_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Health::The University of Sydney School of Pharmacyen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorONG, HUI


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.